4 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Aleece Hobson of HX Venture Fund, Denis Akhiyarov of AiKYNETIX, and Sean Harkins and Brien Beach of AMPD Labs. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from additive manufacturing to venture capital — recently making headlines in Houston innovation.

Aleece Hobson, venture partner for the HX Venture Fund

Aleece Hobson of HX Venture Fund shares what people can expect from Venture Houston on this week's episode of the Houston Innovators Podcast. Photo courtesy of HXVF

Today is a big day for Aleece Hobson — venture partner for the HX Venture Fund, a fund of funds investing in venture capital firms across the country that have interest in investing in Houston companies. She joined the Houston Innovators Podcast last week to discuss Venture Houston, which takes place today, and why it is so important to HXVF to showcase Houston.

"Houston is a destination for innovation — we are not a flyover city," she says on the show. Click here to read more and stream the podcast.

Denis Akhiyarov, CEO and co-founder of AiKYNETIX

Houston-based AiKYNETIX is equipping runners with high-tech tracking tools. Image courtesy of AiKYNETIX

Houstonain Denis Akhiyarov wanted to design a way to easily improve running performance. He founded AiKYNETIX uses real-time technology to provide a new option for runners on treadmills.

“Runners spend a lot of time, energy and money to run better,” says Akhiyarov, CEO and co-founder of the company. “In my personal life with training for nine marathons, I’ve seen limitations with wearables, they don’t actually track running form while running. Overall, our technology tracks not only your basic parameters but it can also analyze the human running form while in motion.”

AiKYNETIX, which was founded in January 2021, is positioned to replace power meters and can make a treadmill smarter. It has ability to plug into interactive video platforms for sports and serves as a much cheaper and more widely available analysis tool outside of motion capture labs, he says. Click here to read more.

Sean Harkins and Brien Beach, co-founders of AMPD Labs

Sean Harkins and Brien Beach opened AmPd Labs' space in the Heights last month. Images via ampdlabs.llc

Last year, Sean Harkins introduced his friend Brien Beach to the world of additive manufacturing, and together the duo saw a business opportunity not only for themselves — but also for all of Houston.

Harkins had been working in 3D printing and additive manufacturing — the process of creating an object by building it one layer at a time — for the last decade and studied industrial design at the University of Houston. Working together, Harkins and Beach launched AmPd Labs, Houston’s next-generation additive manufacturing facility for industrial design and production.

“There is a hill to climb with market acceptance, but we want to be the champions of that and Houston is just a great place to start this because it's the largest industrial city in America and there's so much industry here and there's tons of engineers in this community,” says Beach. “Houston is such a business-forward place. A ‘how can I help you’ type of business place.” Click here to read more.

Houston-based AiKYNETIX is equipping runners with high-tech tracking tools. Image courtesy of AiKYNETIX

Houston sports tech startup is enhancing performance metrics for runners and athletes

sweat tech

With the Houston Marathon only five months away, a new application using human motion insights could help a runner refine their form to reach peak performance – all from the convenience of their smart phone.

While traditional treadmills are limited in training feedback and wearables are not designed to track elevation, Houston-based AiKYNETIX uses real-time technology to provide a new option for runners on treadmills.

“Runners spend a lot of time, energy and money to run better,” says Denis Akhiyarov, CEO and co-founder. “In my personal life with training for nine marathons, I’ve seen limitations with wearables, they don’t actually track running form while running. Overall, our technology tracks not only your basic parameters but it can also analyze the human running form while in motion.”

AiKYNETIX, which was founded in January 2021, is positioned to replace power meters and can make a treadmill smarter. It has ability to plug into interactive video platforms for sports and serves as a much cheaper and more widely available analysis tool outside of motion capture labs, he says.

“Motion analysis is becoming important in sports,” says Akhiyarov, a data scientist who previously worked as a developer in machine learning. “We want to make this expensive fitness technology available for everyone.”

The current target market for the technology is tech-savvy triathletes, however, there are wider applications for the technology including for coaches to get real-time performance metrics. Also, there are medical applications such as for rehabilitation and injury prevention.

“One of the discoveries for us is seeing differences between runners using different shoes,” says cofounder and Rice University MBA Anton Galvas. “It’s very interesting to see how much energy you preserve depending on what kind of shoe you wear.”

The team’s primary market for sale is the IOS app store but they plan to expand to fitness platforms for integration and have seen interest from treadmill companies for potential partnerships.

There are other current competitor solutions that require special hardware and wearables but set up can be cumbersome and if performed in a running lab, it can be very costly for the user. The AiKYNETIX platform is a downloadable app that has a $10 monthly subscription and can be set up with only a tripod.

Within six months of launching, the technology was being tested in a professional lab to track 360 different running conditions. AiKINETIX is a finalist of CodeLaunch accelerator and has moved into phase 1 with America’s Seed Fund powered by the National Science Foundation.

AiKYNETIX has experts and consultants with experience at NASA, Major League Baseball, and European Soccer League.

The AiKYNETIX team is raising seed funding to help to accelerate the development of the app to go to a wider market. The team will also host a showcase of the technology at the grand opening of the fitness center at The Ion this month.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings